Replies to post #410947 on Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

Maybe IB or namtae can stickie post that for you

[30thirdwart]

yes sticky.- excellent post.

[JamesF1]

My guess is Vyvanse generic news comes around thanksgiving time. If the news is positive ELTP shareholders will have a lot to be thankful about. Lol

[jammy32]

What about the billion shares

[HGiLS]

Hey Moderators - The post of BNGO is a candidate to be pinned.

My 43 cents :-)

------------
Updated Drug Manufacturers -
Specialty & Generic
P/E is ~ 33.64 currently

https://fullratio.com/pe-ratio-by-industry

Elite’s current EPS is $0.0191

EPS x P/E = SP
$0.0191 x 33.64 = $0.6425

ELTP share price could be ~$0.6425 right now based on this calculation.

As more products are launched and more revenue comes in, then it will drive up the EPS and the price per share should go much higher than $1.

Elite’s revenue was ~$56.6 million for the last fiscal year.

Imagine what the share price can be
if Elite’s revenue is ~$566 million for all the drugs that are approved for launch and those about to be approved in the pipeline.

10 fold on EPS could be $0.191

$0.191 x 33.64 = $6.425

And this price per share is not even factoring the potential of Elite’s future, Abuse Resistant Technology branded drugs.

1. oxycodone with naltrexone (SequestOx)
2. hydrocodone with naltrexone
3. oxymorphone with naltrexone
4. hydromorphone with naltrexone
5. morphine sulfate with naltrexone

Nasdaq listed is within reach.
Buy out offer is plausible.

My current road map with investing in ELTP.

At least 5 more press releases are about to be announced in the very near future.

ELTP approved drugs with pending launches:

1. Methotrexate
$64 million market
Just launched on 8/27/24

https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=137279&BzID=2258&g=939&Nav=0&LangID=1&s=0 (https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=137279&BzID=2258&g=939&Nav=0&LangID=1&s=0)

If I can remember correctly,
ELTP shares jumped from ~$0.20 to ~$0.40 from that press release, the previous record earnings press release, and conference call.

2. Codeine with acetaminophen
$45 million market
Launched on 10/7/24

https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=138878&BzID=2258&g=939&Nav=0&LangID=1&s=0

3. Record earnings conference call
11/14/24
Press release #1

4. Generic Percocet
oxycodone with acetaminophen
$500 million market
Will launch 6-8 weeks after the codeine with acetaminophen launch
Press Release #2
As early as 11/18/24

5. Generic Norco
hydrocodone with acetaminophen
$477 million market
Will launch 6-8 weeks after the oxycodone with acetaminophen launch
Press Release #3
As early as 12/30/24

6. Dolophine/Methadone
$30 million market
Will launch 6-8 weeks after the hydrocodone with acetaminophen launch
Press Release #4
As early as 2/14/25

7. Pending approval:
Generic Vyvanse
$5.1 billion market
This is the monster news that everyone is waiting for.
Hopefully the approvable positive press release will come out by November 2024.
Press Release #5

Launch of Generic Vyvanse
Press Release #6

Pending approval for launch:
Generic OxyContin
$720 million market
Press release #7

Pending approval for launch:
Generic Vigabatrin
$233 Million market
Press release #8

Pending BE equivalent study result:
Generic Concerta
$1.2 billion market
Press release #9

Pending submittal:
Generic Requip XL or
Generic Mirapex ER
$12 Million market
Press release #10

$64 million
+ $45 million
+ $500 million
+ $477 million
+ $30 million
+ $720 million
+ $233 million
+ $12 million
= $2.081 billion

$2.081 billion
+ $5.1 billion
+ $1.2 billion
= $8.381 billion market

CEO Nasrat Hakim still holds 221,572,000 shares.

It is in his best interest to continue to provide the rocket fuel for ELTP.

Therefore, we can expect more higher revenue drugs in the pipeline soon for more BE studies since Elite now has money to do so.

https://finance.yahoo.com/quote/ELTP?p=ELTP

[NASDAQ2020]

IB or namtae will probably stickie this for the MB

[Dr Speculator Ninja]

MODS - Please sticky this Bngo post:

Updated Drug Manufacturers -
Specialty & Generic
P/E is ~ 33.64 currently

https://fullratio.com/pe-ratio-by-industry

Elite’s current EPS is $0.0191

EPS x P/E = SP
$0.0191 x 33.64 = $0.6425

ELTP share price could be ~$0.6425 right now based on this calculation.

As more products are launched and more revenue comes in, then it will drive up the EPS and the price per share should go much higher than $1.

Elite’s revenue was ~$56.6 million for the last fiscal year.

Imagine what the share price can be
if Elite’s revenue is ~$566 million for all the drugs that are approved for launch and those about to be approved in the pipeline.

10 fold on EPS could be $0.191

$0.191 x 33.64 = $6.425

And this price per share is not even factoring the potential of Elite’s future, Abuse Resistant Technology branded drugs.

1. oxycodone with naltrexone (SequestOx)
2. hydrocodone with naltrexone
3. oxymorphone with naltrexone
4. hydromorphone with naltrexone
5. morphine sulfate with naltrexone

Nasdaq listed is within reach.
Buy out offer is plausible.

My current road map with investing in ELTP.

At least 5 more press releases are about to be announced in the very near future.

ELTP approved drugs with pending launches:

1. Methotrexate
$64 million market
Just launched on 8/27/24

https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=137279&BzID=2258&g=939&Nav=0&LangID=1&s=0 (https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=137279&BzID=2258&g=939&Nav=0&LangID=1&s=0)

If I can remember correctly,
ELTP shares jumped from ~$0.20 to ~$0.40 from that press release, the previous record earnings press release, and conference call.

2. Codeine with acetaminophen
$45 million market
Launched on 10/7/24

https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=138878&BzID=2258&g=939&Nav=0&LangID=1&s=0

3. Record earnings conference call
11/14/24
Press release #1

4. Generic Percocet
oxycodone with acetaminophen
$500 million market
Will launch 6-8 weeks after the codeine with acetaminophen launch
Press Release #2
As early as 11/18/24

5. Generic Norco
hydrocodone with acetaminophen
$477 million market
Will launch 6-8 weeks after the oxycodone with acetaminophen launch
Press Release #3
As early as 12/30/24

6. Dolophine/Methadone
$30 million market
Will launch 6-8 weeks after the hydrocodone with acetaminophen launch
Press Release #4
As early as 2/14/25

7. Pending approval:
Generic Vyvanse
$5.1 billion market
This is the monster news that everyone is waiting for.
Hopefully the approvable positive press release will come out by November 2024.
Press Release #5

Launch of Generic Vyvanse
Press Release #6

Pending approval for launch:
Generic OxyContin
$720 million market
Press release #7

Pending approval for launch:
Generic Vigabatrin
$233 Million market
Press release #8

Pending BE equivalent study result:
Generic Concerta
$1.2 billion market
Press release #9

Pending submittal:
Generic Requip XL or
Generic Mirapex ER
$12 Million market
Press release #10

$64 million
+ $45 million
+ $500 million
+ $477 million
+ $30 million
+ $720 million
+ $233 million
+ $12 million
= $2.081 billion

$2.081 billion
+ $5.1 billion
+ $1.2 billion
= $8.381 billion market

CEO Nasrat Hakim still holds 221,572,000 shares.

It is in his best interest to continue to provide the rocket fuel for ELTP.

Therefore, we can expect more higher revenue drugs in the pipeline soon for more BE studies since Elite now has money to do so.

https://finance.yahoo.com/quote/ELTP?p=ELTP